Mar 28, 2022|
JD Health Releases 2021 Annual Results
by Vivian Yang
JD Health released its 2021 financial year annual results on March 28th, the company’s second full-year earnings release after its listing on Hong Kong Stock Exchange (6618.HK) on Dec. 8, 2020. The company announced net revenue of RMB 30.68 billion yuan, an increase of 58.3% year on year. Profit (on a non-IFRS basis) was RMB 1.4 billion yuan, up by 91.5% YoY.
JD Health’s business maintained strong growth momentum in 2021, driven by a growing user base and improvements to the user experience. On Dec. 21, 2021, annual active user accounts reached 123 million, representing a net addition of over 33.56 million from the 12-month period ended December 31, 2020. Additionally, its online medical consultation service grew rapidly, with its daily average consultations exceeding 190,000.
In his letter to shareholders, JD Health CEO Enlin Jin wrote that “over the past year, under the guidance of the relevant policies and regulations, and adhering to long-term value, JD Health consistently enhanced its capabilities by opening its ‘retail pharmacy + healthcare service’ ecosystem, helping the upstream, midstream and downstream entities in the industry in their digital transformation, and thus providing quality healthcare services to a wider group of people.”
In addition, “by offering professional supply chain and technology solutions, we served a growing number of local government departments and medical institutions, which accelerated the digital transformation of the healthcare industry and promoted the deeper integration and development of China’s digital and real economy,” Jin noted.
With the business philosophy of “based on trust and focusing on customer’s health”, JD Health is committed to improving inclusive healthcare for Chinese people at large while creating long-term and sustainable value for shareholders and the society.
According to the release, as of the end of 2021 JD Health has been leveraging 19 medicine warehouses and over 400 non-medicine warehouses across the country to realize next-day delivery of more than 80% of its self-operated medicines, and JD Pharmacy is able to deliver cold-chain pharmaceutical products in over 200 cities in China through its proprietary cold-chain logistics network.
JD Health continued to deepen collaborations with leading pharmaceutical companies such as Sanofi China, UCB China, Novartis and more, and became their first choice to release new medicines for online sales as well as a preferred partner to explore digital marketing innovations.
On the development of JD Health’s internet hospital, more than 45,000 doctors with the level of deputy chief physicians (second highest of medical professional title in China) and above have joined JD Health, and together collectively handled a daily average of more than 190,000 online consultations last year. Meanwhile, nine specialized medical centers for infection and liver diseases, brain nutrition, skin repair and more were established, bringing the overall number of specialized medical centers to 27 under JD Health’s internet hospital.
The “Family Doctor” telemedicine program continues to consolidate medical services and products’ resources and provide more diversified service scenarios to users, such as online video or audio consultations that support multiple users’ same time chat, service provision to grassroots communities and more.
In the past year, JD Health’s Rare Diseases Care Project and Fund have helped more than 24,000 patients acquire medications and healthcare services. And the company went full-force for the anti-COVID fight in different regions in China and natural disaster relief such as the flood in Henan province by donating medical supplies and offering voluntary health consultation services both online and offline.
Read the full report of JD Health’s annual results 2021 here.